1. Home
  2. HURA vs AMTX Comparison

HURA vs AMTX Comparison

Compare HURA & AMTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • AMTX
  • Stock Information
  • Founded
  • HURA 2009
  • AMTX 2005
  • Country
  • HURA United States
  • AMTX United States
  • Employees
  • HURA N/A
  • AMTX N/A
  • Industry
  • HURA
  • AMTX Major Chemicals
  • Sector
  • HURA
  • AMTX Industrials
  • Exchange
  • HURA Nasdaq
  • AMTX Nasdaq
  • Market Cap
  • HURA 145.6M
  • AMTX 150.1M
  • IPO Year
  • HURA N/A
  • AMTX N/A
  • Fundamental
  • Price
  • HURA $2.37
  • AMTX $2.18
  • Analyst Decision
  • HURA Strong Buy
  • AMTX Strong Buy
  • Analyst Count
  • HURA 2
  • AMTX 3
  • Target Price
  • HURA $11.50
  • AMTX $17.00
  • AVG Volume (30 Days)
  • HURA 823.7K
  • AMTX 577.4K
  • Earning Date
  • HURA 08-14-2025
  • AMTX 08-07-2025
  • Dividend Yield
  • HURA N/A
  • AMTX N/A
  • EPS Growth
  • HURA N/A
  • AMTX N/A
  • EPS
  • HURA N/A
  • AMTX N/A
  • Revenue
  • HURA N/A
  • AMTX $223,574,000.00
  • Revenue This Year
  • HURA N/A
  • AMTX $21.25
  • Revenue Next Year
  • HURA N/A
  • AMTX $98.10
  • P/E Ratio
  • HURA N/A
  • AMTX N/A
  • Revenue Growth
  • HURA N/A
  • AMTX N/A
  • 52 Week Low
  • HURA $1.80
  • AMTX $1.22
  • 52 Week High
  • HURA $8.40
  • AMTX $4.73
  • Technical
  • Relative Strength Index (RSI)
  • HURA 38.05
  • AMTX 34.23
  • Support Level
  • HURA $2.43
  • AMTX $2.57
  • Resistance Level
  • HURA $2.65
  • AMTX $2.80
  • Average True Range (ATR)
  • HURA 0.18
  • AMTX 0.15
  • MACD
  • HURA -0.07
  • AMTX -0.03
  • Stochastic Oscillator
  • HURA 5.39
  • AMTX 1.57

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About AMTX Aemetis Inc. (DE)

Aemetis Inc is an renewable fuel and biochemicals company focused on the production of renewable fuels and chemicals through the acquisition, development and commercialization of technologies that replace traditional petroleum-based products through the conversion of first-generation ethanol and biodiesel plants into biorefineries. It owns and operates an approximately 65 million gallon per year ethanol production facility located in Keyes, California. In addition to low carbon renewable fuel ethanol, the Keyes Plant produces Wet Distillers Grains, Distillers Corn Oil, and Condensed Distillers Solubles, all of which are sold to local dairies and feedlots as animal feed. It operates in the reportable geographic segments of North America and India.

Share on Social Networks: